1) A large study in India found that two doses of the HPV vaccine, administered 6 months apart, were as effective at preventing HPV infection as three doses in girls aged 10-18 years.
2) The two-dose schedule produced similar antibody levels and no cases of persistent infection with HPV types 16 and 18 were found over an average follow up of 4.7 years.
3) Based on these results, the study supports the WHO recommendation of a two-dose schedule of the HPV vaccine for young girls.
HPV Vaccination, Cerviocal Cancer : Do we need it
for Prevention of cervical cancer &
other HPV related diseasesm,
Presentation Outlines
Cervical cancer disease burden
Prevention with HPV vaccination
Vaccination of sexually active women
Opportunity of Postpartum HPV vaccination
Importance of genital warts prevention
Real world effectiveness data
Safety of HPV vaccine
This document discusses HPV vaccines and cervical cancer prevention. It provides details on HPV types, transmission, and associated cancers. It outlines recommendations for HPV vaccination including target groups, dosing schedules, and delivery strategies. The goals of HPV vaccination are to reduce the global burden of HPV-related cancers through immunization programs.
Cervical Cancer Vaccine - Do we need it in IndiaGaurav Gupta
The document discusses cervical cancer and the HPV virus. It provides epidemiological data on cervical cancer in India, describing it as the most common cancer in Indian women. It explains the link between HPV infection and cervical cancer, noting that HPV vaccination can prevent most cervical cancers. The document discusses two approved HPV vaccines, Gardasil and Cervarix, comparing their efficacy, safety and immune responses elicited. It recommends HPV vaccination as an important strategy for cervical cancer prevention.
AN OPPORTUNITY FOR HPV VACCINATION , Dr. Sharda Jain Lifecare Centre Lifecare Centre
This document discusses strategies for cervical cancer prevention in India through HPV vaccination. It notes that cervical cancer is almost entirely preventable but prevention efforts in India have been inadequate. HPV vaccination provides strong protection, especially if received before sexual debut. However, vaccination rates in India are very low. The document argues that the postpartum period provides an opportunity for catch-up HPV vaccination that can improve coverage. Several studies show high HPV prevalence in postpartum women, demonstrating the potential benefit. Other evidence suggests postpartum women are receptive to vaccination and compliance with the 3 dose schedule can be high with proper counseling. The document advocates that healthcare providers should recommend HPV vaccination to women in the postpartum period to help control cervical cancer in India
This document summarizes a panel discussion on HPV vaccination in India. Some key points:
- Cervical cancer is a major problem in India, with over 122,000 new cases and 67,000 deaths annually.
- HPV is the primary cause of cervical cancer. Vaccination induces high antibody levels to protect against HPV types 16 and 18, which cause 70% of cervical cancers.
- The best age for vaccination is 11-12 years, before sexual debut. Catch-up vaccination is recommended through age 26.
- Common side effects of HPV vaccination are mild and temporary. Rare severe allergic reactions may occur.
- Vaccination is recommended even for sexually active women and women in monogamous relationships to
The 9-valent HPV vaccine (9vHPV) was found to prevent infection and disease caused by HPV types 31, 33, 45, 52, and 58 beyond those already covered by the quadrivalent HPV vaccine (HPV types 6, 11, 16, and 18). A randomized, double-blind study of 14,215 women aged 16-26 found that 9vHPV generated antibody responses to HPV types 6, 11, 16, and 18 that were not inferior to the quadrivalent vaccine. Additionally, rates of HPV related disease for those types were similar between the two groups. Adverse events were generally comparable, though injection site reactions were more common for 9vHPV. The 9vHPV
Cervical cancer is the second most common cancer in women worldwide. The document discusses opportunities and challenges for cervical cancer prevention including new HPV vaccines and screening assays. It provides an overview of HPV vaccines, countries that have introduced them, and challenges to introduction. Monitoring vaccine coverage and impact is also discussed.
HPV Vaccination, Cerviocal Cancer : Do we need it
for Prevention of cervical cancer &
other HPV related diseasesm,
Presentation Outlines
Cervical cancer disease burden
Prevention with HPV vaccination
Vaccination of sexually active women
Opportunity of Postpartum HPV vaccination
Importance of genital warts prevention
Real world effectiveness data
Safety of HPV vaccine
This document discusses HPV vaccines and cervical cancer prevention. It provides details on HPV types, transmission, and associated cancers. It outlines recommendations for HPV vaccination including target groups, dosing schedules, and delivery strategies. The goals of HPV vaccination are to reduce the global burden of HPV-related cancers through immunization programs.
Cervical Cancer Vaccine - Do we need it in IndiaGaurav Gupta
The document discusses cervical cancer and the HPV virus. It provides epidemiological data on cervical cancer in India, describing it as the most common cancer in Indian women. It explains the link between HPV infection and cervical cancer, noting that HPV vaccination can prevent most cervical cancers. The document discusses two approved HPV vaccines, Gardasil and Cervarix, comparing their efficacy, safety and immune responses elicited. It recommends HPV vaccination as an important strategy for cervical cancer prevention.
AN OPPORTUNITY FOR HPV VACCINATION , Dr. Sharda Jain Lifecare Centre Lifecare Centre
This document discusses strategies for cervical cancer prevention in India through HPV vaccination. It notes that cervical cancer is almost entirely preventable but prevention efforts in India have been inadequate. HPV vaccination provides strong protection, especially if received before sexual debut. However, vaccination rates in India are very low. The document argues that the postpartum period provides an opportunity for catch-up HPV vaccination that can improve coverage. Several studies show high HPV prevalence in postpartum women, demonstrating the potential benefit. Other evidence suggests postpartum women are receptive to vaccination and compliance with the 3 dose schedule can be high with proper counseling. The document advocates that healthcare providers should recommend HPV vaccination to women in the postpartum period to help control cervical cancer in India
This document summarizes a panel discussion on HPV vaccination in India. Some key points:
- Cervical cancer is a major problem in India, with over 122,000 new cases and 67,000 deaths annually.
- HPV is the primary cause of cervical cancer. Vaccination induces high antibody levels to protect against HPV types 16 and 18, which cause 70% of cervical cancers.
- The best age for vaccination is 11-12 years, before sexual debut. Catch-up vaccination is recommended through age 26.
- Common side effects of HPV vaccination are mild and temporary. Rare severe allergic reactions may occur.
- Vaccination is recommended even for sexually active women and women in monogamous relationships to
The 9-valent HPV vaccine (9vHPV) was found to prevent infection and disease caused by HPV types 31, 33, 45, 52, and 58 beyond those already covered by the quadrivalent HPV vaccine (HPV types 6, 11, 16, and 18). A randomized, double-blind study of 14,215 women aged 16-26 found that 9vHPV generated antibody responses to HPV types 6, 11, 16, and 18 that were not inferior to the quadrivalent vaccine. Additionally, rates of HPV related disease for those types were similar between the two groups. Adverse events were generally comparable, though injection site reactions were more common for 9vHPV. The 9vHPV
Cervical cancer is the second most common cancer in women worldwide. The document discusses opportunities and challenges for cervical cancer prevention including new HPV vaccines and screening assays. It provides an overview of HPV vaccines, countries that have introduced them, and challenges to introduction. Monitoring vaccine coverage and impact is also discussed.
Global lung cancer vaccine market & pipeline insight 2015KuicK Research
“Global Lung Cancer Vaccine Market & Pipeline Insight 2015” Report Highlights:
Introduction to Lung Cancer Vaccine
Global Lung Cancer Vaccine Market Analysis
Global Lung Cancer Vaccine Pipeline by Company & Phase
Global Lung Cancer Vaccine Pipeline: 29 Vaccines
Majority Lung Cancer Vaccines in Phase-II: 8 Vaccines
Marketed Lung Cancer Vaccines: 3 ( BV NSCLC 001, Mycidac-C™ & Vaxira®)
Personalized Cancer Vaccines: Progress & Possibilities
Lung Cancer Vaccine Mechanism
HPV Vaccination Update in 2021 Dr Sharda Jain Lifecare Centre
This document discusses the importance of prioritizing HPV vaccination in India. It notes that cervical cancer is a major problem in India, with over 60,000 deaths per year. However, HPV vaccination rates in India are less than 1%. The document advocates scaling up HPV vaccination programs for adolescent girls according to WHO guidelines. Vaccinating girls before age 15 is key to eliminating cervical cancer as a public health problem. It also discusses opportunities for catch-up vaccination by OBGYNs and nurses when women visit for other women's health issues. The overall message is that HPV vaccination should be a top priority for the Indian government to substantially reduce the cervical cancer burden.
This document discusses recommendations from the Advisory Committee on Immunization Practices and the American Academy of Pediatrics regarding HPV vaccination. It recommends routine HPV vaccination for all 11-12 year old children with either the quadrivalent or bivalent HPV vaccine. HPV vaccines protect against cancers caused by HPV types 16 and 18. The rationale for recommending vaccination at ages 11-12 is that the vaccine works best before sexual activity begins and antibody responses are highest during these ages. Vaccinating males provides direct benefits to males and also indirect herd immunity benefits to females.
The document discusses HPV vaccine recommendations and current issues. It provides an overview of HPV vaccine licensure and recommendations, safety data showing the vaccines are very safe, and low national and state HPV vaccination rates, especially for certain populations. Rates in Indiana are among the lowest in the US. It recommends new strategies are needed to increase HPV vaccine acceptance and reduce disparities.
This document discusses strategies for improving adult vaccination rates in rural Indiana by empowering healthcare providers. It describes an educational initiative developed by the Indiana Immunization Coalition and Indiana Faculty to provide providers with information on communicating vaccine benefits to patients, identifying patient barriers to vaccination, and applying system changes to address provider barriers. The goal is to help integrate adult vaccination screening and administration into clinical practice.
UPDATE HPV Vaccination IN Cervical Cancer Prevention Dr Sharda Jain Lifecare Centre
Cervical Cancer In India: A Preventable Tragedy That Requires Urgent Attention
It is estimated that in India, about 160 million women aged 30-59 years are at risk of developing cervical cancer, with fatality rate of 50 per cent
The document provides biographical information about Dr. Narendra Malhotra, an obstetrician gynecologist from Agra, India. It notes that he has served as the president of FOGSI, dean of ICMU, and director of Ian Donald School of Ultrasound. It also lists his accomplishments, publications, areas of special interest, and contact information for his practice.
Mission SAY No to Cervical Cancer With HPV Vaccination DR. SHARDA JAIN S...Lifecare Centre
1. Cervical cancer is a major health issue in India, accounting for 23% of new cervical cancer cases and 25% of cervical cancer deaths worldwide.
2. Human papillomavirus (HPV) infection causes cervical cancer, with vaccination providing 98-100% efficacy against HPV types.
3. Screening and vaccination can help prevent cervical cancer, but coverage in India remains low due to cost and lack of national programs.
Human papillomavirus (HPV) causes cervical cancer being the fourth most common cancer in women. 99% of all cervical cancer cases are related to genital infection with HPV. HPV Vaccines are now available and are the springboard for a change by primary prevention of this threatening situation.
Two – Dose regime of 4HPV : Indian Perspective Dr. Jyoti Agarwal Dr. Sharda J...Lifecare Centre
Aim
To compare the immunogenicity and frequency of persistent infection and cervical precancerous lesions caused by vaccine-targeted HPV after vaccination with:
Two doses of quadrivalent vaccine on days 1 and 180 or later
With three doses on days 1, 60, and 180 or later, in a cluster-randomised trial
Cancer Biomarkers Research, HPV and Cancer, HPV VaccineJames Lyons-Weiler
The document discusses HPV (human papillomavirus) and cancer biomarkers. It notes that HPV vaccines target certain high-risk HPV types linked to cancers like cervical cancer. Some studies have found evidence of "type replacement" where non-vaccine HPV types increase in prevalence after vaccination, potentially limiting vaccine effectiveness. However, other studies have not found clear evidence of type replacement or have dismissed observed increases in non-vaccine types. There is ongoing debate about the ability of HPV vaccines to prevent cancer and their long-term safety profile based on limitations in clinical trials.
Gardasil - Do we need Cervical Cancer Vaccine in India?Gaurav Gupta
The document provides an overview of HPV disease and the case for HPV vaccination. It discusses the high global and Indian disease burden of cervical cancer caused by HPV, with India accounting for over 27% of new cervical cancer cases and deaths worldwide despite having a small fraction of the global population. Clinical trial data demonstrates over 90% efficacy of the quadrivalent HPV vaccine in preventing cervical, vulvar, vaginal, and anal cancers and genital warts caused by HPV types 6, 11, 16, and 18. Long-term follow up studies show sustained immune memory response and protection for over 7 years. Worldwide and Indian guidelines recommend HPV vaccination for girls aged 9-14 years.
The United States Congress designated January as Cervical Health Awareness Month.
CANSA places the focus on Cervical Cancer during the month of September. Cervical Cancer is the 2nd most common cancer among South African women.
Sources: http://www.cansa.org.za/womens-health/
HPV Infection , HPV Vaccination , Cervical cancer , Cancer in India , Dr. SHA...Lifecare Centre
HPV inefection , HPV disease prevention, Cervical cancer prevention , Cervical cancer treatment, Female cancer , Female cancer prevention , Uterine cancer , Cancer in india
HPV Vaccination & Ca. Cervix Screening Update Dr. Sharda Jain Dr. Jyoti A...Lifecare Centre
The document discusses the disease burden of cervical cancer in India, providing statistics showing that India accounts for approximately 25-27% of new cervical cancer cases and deaths worldwide despite having a smaller population than other parts of the world. It then discusses the role of HPV in causing cervical cancer, noting that HPV types 16 and 18 cause over 70% of cases. The document recommends HPV vaccination between ages 9-13 when immune response is strongest, and suggests it can provide benefits even for some sexually active women who have not been exposed to all HPV types covered by the vaccine. Long-term follow-up studies show the vaccine continues to provide nearly 100% effectiveness against HPV 16/18-related cervical diseases for many years.
HPV Diseases More Than Cervical Cancer, Dr. Sharda Jain Lifecare Centre
HPV Disease . Cervical cancer , prevention cervical cancer , HPV prevention , cancer prevention , Human Papillomavirus (HPV), cervical cancer prevention
The document discusses HPV vaccination and the challenges of implementing widespread vaccination programs. It summarizes that HPV vaccination has been shown to be highly effective in preventing HPV infection and cervical lesions in clinical trials. However, public acceptability and the duration of vaccine protection remain challenges. Public education efforts will be needed to encourage vaccination of teenage girls, and it is unclear if booster shots will be required to maintain long-term protection. Universal vaccination of both males and females may help maximize the benefits of HPV vaccination programs.
This PowerPoint presentation summarizes information about HPV (human papillomavirus) and the HPV vaccine. It discusses what HPV is, how common it is, how the vaccine works to prevent infection from high-risk HPV types, who should receive the vaccine, and the link between HPV and certain cancers. It also notes potential signs and symptoms of HPV infection and addresses an opposing viewpoint that the vaccine is expensive and can cause side effects in some cases.
The document discusses HPV vaccination, including:
1) Cervical cancer is a major disease burden in India, with India accounting for about 25% of cervical cancer deaths worldwide. HPV is the cause of nearly all cervical cancers.
2) HPV vaccination aims to prevent cervical cancer by vaccinating against HPV types 16 and 18, which cause about 70% of cervical cancers. Vaccination is recommended for girls and women between ages 9-45 before sexual debut or exposure to HPV.
3) Real-world effectiveness data from Australia's HPV vaccination program shows decreases in HPV vaccine-type infections and high-grade cervical abnormalities in young women following the program.
The document provides a detailed history of vaccinations from ancient times through modern times. It describes key events such as Edward Jenner discovering the smallpox vaccine in 1796. It also summarizes the four main types of vaccines - live attenuated, inactivated, subunit, and toxoid vaccines - and provides examples of each. Common questions about vaccinations are addressed at the end related to safety, schedules, and specific vaccines.
Global lung cancer vaccine market & pipeline insight 2015KuicK Research
“Global Lung Cancer Vaccine Market & Pipeline Insight 2015” Report Highlights:
Introduction to Lung Cancer Vaccine
Global Lung Cancer Vaccine Market Analysis
Global Lung Cancer Vaccine Pipeline by Company & Phase
Global Lung Cancer Vaccine Pipeline: 29 Vaccines
Majority Lung Cancer Vaccines in Phase-II: 8 Vaccines
Marketed Lung Cancer Vaccines: 3 ( BV NSCLC 001, Mycidac-C™ & Vaxira®)
Personalized Cancer Vaccines: Progress & Possibilities
Lung Cancer Vaccine Mechanism
HPV Vaccination Update in 2021 Dr Sharda Jain Lifecare Centre
This document discusses the importance of prioritizing HPV vaccination in India. It notes that cervical cancer is a major problem in India, with over 60,000 deaths per year. However, HPV vaccination rates in India are less than 1%. The document advocates scaling up HPV vaccination programs for adolescent girls according to WHO guidelines. Vaccinating girls before age 15 is key to eliminating cervical cancer as a public health problem. It also discusses opportunities for catch-up vaccination by OBGYNs and nurses when women visit for other women's health issues. The overall message is that HPV vaccination should be a top priority for the Indian government to substantially reduce the cervical cancer burden.
This document discusses recommendations from the Advisory Committee on Immunization Practices and the American Academy of Pediatrics regarding HPV vaccination. It recommends routine HPV vaccination for all 11-12 year old children with either the quadrivalent or bivalent HPV vaccine. HPV vaccines protect against cancers caused by HPV types 16 and 18. The rationale for recommending vaccination at ages 11-12 is that the vaccine works best before sexual activity begins and antibody responses are highest during these ages. Vaccinating males provides direct benefits to males and also indirect herd immunity benefits to females.
The document discusses HPV vaccine recommendations and current issues. It provides an overview of HPV vaccine licensure and recommendations, safety data showing the vaccines are very safe, and low national and state HPV vaccination rates, especially for certain populations. Rates in Indiana are among the lowest in the US. It recommends new strategies are needed to increase HPV vaccine acceptance and reduce disparities.
This document discusses strategies for improving adult vaccination rates in rural Indiana by empowering healthcare providers. It describes an educational initiative developed by the Indiana Immunization Coalition and Indiana Faculty to provide providers with information on communicating vaccine benefits to patients, identifying patient barriers to vaccination, and applying system changes to address provider barriers. The goal is to help integrate adult vaccination screening and administration into clinical practice.
UPDATE HPV Vaccination IN Cervical Cancer Prevention Dr Sharda Jain Lifecare Centre
Cervical Cancer In India: A Preventable Tragedy That Requires Urgent Attention
It is estimated that in India, about 160 million women aged 30-59 years are at risk of developing cervical cancer, with fatality rate of 50 per cent
The document provides biographical information about Dr. Narendra Malhotra, an obstetrician gynecologist from Agra, India. It notes that he has served as the president of FOGSI, dean of ICMU, and director of Ian Donald School of Ultrasound. It also lists his accomplishments, publications, areas of special interest, and contact information for his practice.
Mission SAY No to Cervical Cancer With HPV Vaccination DR. SHARDA JAIN S...Lifecare Centre
1. Cervical cancer is a major health issue in India, accounting for 23% of new cervical cancer cases and 25% of cervical cancer deaths worldwide.
2. Human papillomavirus (HPV) infection causes cervical cancer, with vaccination providing 98-100% efficacy against HPV types.
3. Screening and vaccination can help prevent cervical cancer, but coverage in India remains low due to cost and lack of national programs.
Human papillomavirus (HPV) causes cervical cancer being the fourth most common cancer in women. 99% of all cervical cancer cases are related to genital infection with HPV. HPV Vaccines are now available and are the springboard for a change by primary prevention of this threatening situation.
Two – Dose regime of 4HPV : Indian Perspective Dr. Jyoti Agarwal Dr. Sharda J...Lifecare Centre
Aim
To compare the immunogenicity and frequency of persistent infection and cervical precancerous lesions caused by vaccine-targeted HPV after vaccination with:
Two doses of quadrivalent vaccine on days 1 and 180 or later
With three doses on days 1, 60, and 180 or later, in a cluster-randomised trial
Cancer Biomarkers Research, HPV and Cancer, HPV VaccineJames Lyons-Weiler
The document discusses HPV (human papillomavirus) and cancer biomarkers. It notes that HPV vaccines target certain high-risk HPV types linked to cancers like cervical cancer. Some studies have found evidence of "type replacement" where non-vaccine HPV types increase in prevalence after vaccination, potentially limiting vaccine effectiveness. However, other studies have not found clear evidence of type replacement or have dismissed observed increases in non-vaccine types. There is ongoing debate about the ability of HPV vaccines to prevent cancer and their long-term safety profile based on limitations in clinical trials.
Gardasil - Do we need Cervical Cancer Vaccine in India?Gaurav Gupta
The document provides an overview of HPV disease and the case for HPV vaccination. It discusses the high global and Indian disease burden of cervical cancer caused by HPV, with India accounting for over 27% of new cervical cancer cases and deaths worldwide despite having a small fraction of the global population. Clinical trial data demonstrates over 90% efficacy of the quadrivalent HPV vaccine in preventing cervical, vulvar, vaginal, and anal cancers and genital warts caused by HPV types 6, 11, 16, and 18. Long-term follow up studies show sustained immune memory response and protection for over 7 years. Worldwide and Indian guidelines recommend HPV vaccination for girls aged 9-14 years.
The United States Congress designated January as Cervical Health Awareness Month.
CANSA places the focus on Cervical Cancer during the month of September. Cervical Cancer is the 2nd most common cancer among South African women.
Sources: http://www.cansa.org.za/womens-health/
HPV Infection , HPV Vaccination , Cervical cancer , Cancer in India , Dr. SHA...Lifecare Centre
HPV inefection , HPV disease prevention, Cervical cancer prevention , Cervical cancer treatment, Female cancer , Female cancer prevention , Uterine cancer , Cancer in india
HPV Vaccination & Ca. Cervix Screening Update Dr. Sharda Jain Dr. Jyoti A...Lifecare Centre
The document discusses the disease burden of cervical cancer in India, providing statistics showing that India accounts for approximately 25-27% of new cervical cancer cases and deaths worldwide despite having a smaller population than other parts of the world. It then discusses the role of HPV in causing cervical cancer, noting that HPV types 16 and 18 cause over 70% of cases. The document recommends HPV vaccination between ages 9-13 when immune response is strongest, and suggests it can provide benefits even for some sexually active women who have not been exposed to all HPV types covered by the vaccine. Long-term follow-up studies show the vaccine continues to provide nearly 100% effectiveness against HPV 16/18-related cervical diseases for many years.
HPV Diseases More Than Cervical Cancer, Dr. Sharda Jain Lifecare Centre
HPV Disease . Cervical cancer , prevention cervical cancer , HPV prevention , cancer prevention , Human Papillomavirus (HPV), cervical cancer prevention
The document discusses HPV vaccination and the challenges of implementing widespread vaccination programs. It summarizes that HPV vaccination has been shown to be highly effective in preventing HPV infection and cervical lesions in clinical trials. However, public acceptability and the duration of vaccine protection remain challenges. Public education efforts will be needed to encourage vaccination of teenage girls, and it is unclear if booster shots will be required to maintain long-term protection. Universal vaccination of both males and females may help maximize the benefits of HPV vaccination programs.
This PowerPoint presentation summarizes information about HPV (human papillomavirus) and the HPV vaccine. It discusses what HPV is, how common it is, how the vaccine works to prevent infection from high-risk HPV types, who should receive the vaccine, and the link between HPV and certain cancers. It also notes potential signs and symptoms of HPV infection and addresses an opposing viewpoint that the vaccine is expensive and can cause side effects in some cases.
The document discusses HPV vaccination, including:
1) Cervical cancer is a major disease burden in India, with India accounting for about 25% of cervical cancer deaths worldwide. HPV is the cause of nearly all cervical cancers.
2) HPV vaccination aims to prevent cervical cancer by vaccinating against HPV types 16 and 18, which cause about 70% of cervical cancers. Vaccination is recommended for girls and women between ages 9-45 before sexual debut or exposure to HPV.
3) Real-world effectiveness data from Australia's HPV vaccination program shows decreases in HPV vaccine-type infections and high-grade cervical abnormalities in young women following the program.
The document provides a detailed history of vaccinations from ancient times through modern times. It describes key events such as Edward Jenner discovering the smallpox vaccine in 1796. It also summarizes the four main types of vaccines - live attenuated, inactivated, subunit, and toxoid vaccines - and provides examples of each. Common questions about vaccinations are addressed at the end related to safety, schedules, and specific vaccines.
Gsk creative development approach final2 lesliemaudipernet
The document outlines strategies for building brand love by focusing on penetrating consumer insights, understanding culture, crafting distinctive brand characters, optimizing creative ideas through consumer feedback, and activating brands across all touchpoints. It provides case studies on how these strategies were applied to help brands like Tums, Advil, Pampers, Nature Valley, and Martell drive deeper connections with consumers through more profound cultural understanding, compelling creative concepts, and fully integrated 360-degree brand experiences.
The new kid on the block - hexavalent vaccinesGaurav Gupta
This document summarizes a presentation on hexavalent vaccines given by Dr. Gaurav Gupta. It discusses the efficacy, safety, and immunogenicity data from clinical trials of hexavalent vaccines compared to whole-cell and other combination vaccines. Indian data is presented from a clinical trial of a hexavalent vaccine administered at 6, 10, and 14 weeks of age showing high rates of seroprotection and a favorable safety profile. Schedules using hexavalent vaccines that include vaccination at birth allow for a simplified 0, 3, +/-1 year immunization schedule for hepatitis B.
1) GSK produces vaccines for diseases like pneumonia, polio, rotavirus, cervical cancer and others. Their vaccines have helped prevent up to 3 million deaths and disability in 750,000 children annually.
2) GSK's cervical cancer vaccine, Cervarix, is dedicated to preventing cervical cancer. Clinical trials showed it has nearly 100% efficacy against HPV types 16 and 18, which cause over 50% of cervical cancer cases. It also has efficacy against other high-risk HPV types and has a good safety profile.
3) GSK provides holistic support for vaccination programs including cold chain management, training, advocacy, and monitoring to help ensure vaccines are effectively delivered and utilized. They aim
MOLECULAR DETECTION OF NOROVIRUS GI AND GII GENOTYPES FROM CHILDREN LESS THAN...Glenton Thabo Moloro
This document provides an introduction and background to a study investigating Norovirus genotypes isolated from diarrheal samples of children less than 2 years of age in the Vhembe District of Limpopo, South Africa. The study aims to characterize Norovirus GI and GII genotypes using RT-PCR to determine the prevalent strains causing diarrhea. The document outlines the history, classification, structure, life cycle, transmission, epidemiology, detection, and vaccine development of Norovirus. It discusses the study rationale of extending knowledge of Norovirus as a cause of severe diarrhea. The objectives are to determine the impact of viral diarrhea on nutrition in children. The study design involves obtaining ethical approval and consent, collecting diarrheal samples from rural
Cervical cancer screening and hpv vaccinationSunita Yadav
This document discusses cervical cancer and its prevention through screening and HPV vaccination. It notes that cervical cancer is the most common cancer in Indian females, with 1 in 5 worldwide cases occurring in India. Regular Pap screening can detect precancerous lesions early and HPV vaccination can prevent infection from high-risk HPV types that cause most cervical cancers. The document provides details on HPV, screening guidelines, abnormal Pap results, and cervical cancer prevention recommendations.
Prevention of rotavirus in india is vaccination the only strategy.Dr. Dharmendra Gahwai
Rotavirus is a major cause of diarrhea in young children in India, resulting in approximately 300,000 deaths per year. While oral rehydration solution can treat dehydration, rotavirus infection has no specific treatment. Rotavirus vaccines have been shown to significantly reduce rotavirus disease and deaths in other countries. For India, introducing an affordable rotavirus vaccine into its national immunization program could cost-effectively prevent thousands of rotavirus-related deaths annually, though overall immunization coverage would need to increase to maximize its impact.
This document discusses cervical cancer and HPV in India. It notes that India accounts for 27% of new cervical cancer cases and deaths worldwide despite having only 16% of the global population. It is estimated that over 365 women will die from cervical cancer daily in India by 2025. HPV is the main cause of cervical cancer and certain HPV types are also associated with other cancers. The document discusses HPV vaccines as the primary prevention for HPV-related diseases and recommends routine vaccination of girls aged 9-12 years along with catch-up vaccination up to age 26. It provides details on the available HPV vaccines and their efficacy, safety and recommended dosage schedules.
Gen. math g11 introduction to functionsliza magalso
This document contains:
1. An outline for a mathematics course covering functions and their graphs, basic business mathematics, and logic.
2. Lessons on identifying functions from relations, evaluating functions, and representing real-life situations using functions including piecewise functions.
3. Examples of evaluating functions, operations on functions, and determining whether a relation is a function.
4. An activity drilling students on identifying functions and non-functions.
Ipv – need of the hour dr gaurav guptaGaurav Gupta
The document discusses the history of polio and polio vaccines such as the inactivated polio vaccine (IPV) and oral polio vaccine (OPV). It notes that while OPV has helped reduce polio cases globally, ongoing issues with OPV include vaccine-derived polio viruses and vaccine-associated paralysis. The document advocates for the increased use of IPV to address these issues and aid in the final push to eradicate polio globally.
La vacuna triple vírica o MMR previene el sarampión, la rubeola y las paperas. Se administra en dos dosis a los 12-15 meses y a los 4-6 años. Fue inventada por Maurice Hilleman y es efectiva en un 95-100% de los casos. Puede causar dolor, fiebre y exantema como reacciones adversas leves.
This document provides an overview of HIV vaccines, including definitions, estimates of herd immunity thresholds for different diseases, types of vaccines, strategies for preventive and therapeutic HIV vaccines, and summaries of clinical trials. It discusses DNA vaccines, viral vector vaccines, dendritic cell vaccines, therapeutic vaccine candidates, and the Canadian HIV Vaccines Initiative.
Rotavirus vaccine presentation Rotateq 28 june 2013Gaurav Gupta
This document discusses rotavirus, a leading cause of severe diarrhea among children under 5 years old globally. It provides an overview of the disease burden in India, differences between the two available rotavirus vaccines (Rotarix and RotaTeq), challenges with vaccine serotype diversity and efficacy, and recommendations from WHO and IAPCOI to include rotavirus vaccination in national immunization programs in developing countries due to the potential for significant impact even with moderate vaccine efficacy.
This document summarizes recent advancements in immunization. It discusses the goals of immunization as preventing disease in individuals and ultimately eradicating diseases worldwide. Data from the US shows significant decreases in morbidity from diseases like smallpox, polio, measles, and haemophilus influenza type B due to immunization programs. It also discusses common concerns parents have about immunization and ways to address those concerns. The document then describes the different types of immunization including active and passive immunization. It provides guidelines for many common vaccines and discusses considerations around vaccine handling, scheduling, and specific diseases.
The universal immunization program and supplementary immunization activities in India face challenges in cold chain management due to aging equipment, inadequate trained staff, and poor monitoring. Maintaining the cold chain is essential for vaccine potency but is made more difficult during large scale immunization campaigns due to the increased vaccine volumes and need for careful planning, equipment preparation, and vaccine delivery and storage. Regular assessment and timely repairs of the cold chain system are needed to ensure vaccines are kept at the proper temperature.
Production and Purification of Virus Like Particle (VLP) based VaccineDr. Priyabrata Pattnaik
This document summarizes a presentation on the production and purification of virus-like particle (VLP) based vaccines. It discusses using hepatitis C VLPs as a model system produced using an insect cell/baculovirus expression platform. Key points covered include:
- Challenges in VLP vaccine production include low yields, stability issues, and difficulties removing baculovirus.
- Hepatitis C VLPs containing E1 and E2 glycoproteins were successfully produced using Sf9 insect cells in a Mobius 3L disposable bioreactor, with comparable results to a glass bioreactor.
- A depth filtration clarification process achieved around 70% DNA clearance while recovering approximately 70
Rotavirus vaccines in India - Whats new in 2021 Gaurav Gupta
This document provides information on Rotavirus gastroenteritis (RVGE) and rotavirus vaccines in India, with a focus on vaccine 116E. It discusses how RVGE is a major cause of childhood diarrhea and mortality in India. It summarizes clinical trial results showing the 116E vaccine is effective at preventing severe RVGE, has a good safety profile with no increased risk of intussusception compared to other vaccines, and provides broad protection against circulating rotavirus strains in India. Phase 3 and 4 trials demonstrated 116E is well-tolerated and effective in preventing severe RVGE in Indian children when administered in a 3-dose schedule.
This document discusses vaccination recommendations for adolescents, preconception, and during pregnancy. It provides guidance on routine vaccinations such as Tdap, HPV, influenza, and meningococcal vaccines for adolescents. It also discusses catch-up vaccinations for hepatitis B, MMR, varicella, hepatitis A, and typhoid. The effectiveness and schedules for 2-dose HPV vaccination in adolescents is reviewed. Preconception vaccination guidance emphasizes determining immune status for rubella, varicella and hepatitis B and vaccinating susceptible women.
- The document discusses recommendations for HPV vaccination from international health organizations. It notes that nearly all cervical cancer cases are caused by HPV and cervical cancer disproportionately impacts women in low and middle income countries.
- Recent evidence from trials shows that a single dose of HPV vaccine can provide similar efficacy to 2-3 doses in preventing cervical precancer and cancer. A single dose schedule could make vaccination programs more affordable and scalable.
- India recently launched its first indigenous HPV vaccine. Experts argue that a national single-dose HPV vaccination program for adolescents in India could substantially reduce cervical cancer rates and help eliminate the disease in the country.
RVGE & vaccination, Indian data with reference to 116EGaurav Gupta
Rotavirus gastroenteritis (RVGE) is a leading cause of severe diarrhea among children under 5 years old in India. The 116E rotavirus vaccine has demonstrated high efficacy against severe RVGE in clinical trials conducted in India. A phase III trial found the 116E vaccine was 56% efficacious against severe RVGE after 1 year and 55% efficacious after 2 years. The 116E vaccine was found to be safe with no increased risk of intussusception compared to other rotavirus vaccines. Additional studies found the 116E vaccine provided strong heterotypic protection against commonly circulating rotavirus genotypes in India and no interference from maternal antibodies.
Human Papillomavirus Immunization completion rates increased by the use of th...inventionjournals
Human Papillomavirus is the most common sexually transmitted infection in the United States and world wide. Vaccination is a critical public health measure for lowering the risk of cervical genital and anal cancers. Overall vaccination rates in the United States are low. This study highlights the need to change practices in primary care clinics to increase Human Papillomavirus vaccination rates. The study compares vaccination rates before and after the introduction of the American Academy of Pediatrics Tool Kit and a staff training session.
Dr. Gaurav Gupta RV 5 Patiala CME 18 feb 2018Gaurav Gupta
Comparing the 4 available Rotavirus vaccines in the Indian context, Rotateq (RV5), Rotavac/ Rotasure (116E), Rotarix (RV1), and Rotasiil (BRV-PV), with special reference to Rotateq.
Into the Vast Unknown: Early Lessons from a PrEP Demonstration Project in Cis-gender Women in Southern California
Jill Blumenthal MD
August 25th, 2017
UCSD HIV & Global Health Rounds
Immunogenicity – i.e. immune response generated in the mother.
Transfer of antibodies to fetus Split –Vision Vaccine
Clinical efficacy in mother
Clinical efficacy in newborn
( up to 6 months of age )
Effectiveness of the Influenza vaccine . Dr. Sharda Jain , Lifecare Cent...Lifecare Centre
Effectiveness of vaccine can be judged in 4 ways
Immunogenicity – i.e. immune response generated in the mother.
Transfer of antibodies to fetus
Clinical efficacy in mother
Clinical efficacy in newborn
( up to 6 months of age )
Post partum period an excellent opportunity for hpv vaccinationLifecare Centre
1) A study in Brazil found that HPV prevalence in young primiparous women was 58.5%, with 17.3% and 13.3% positive for the two high-risk HPV types 16 and 18. This suggests that postpartum vaccination could provide protection against cervical cancer for most women.
2) A US study found high acceptance of postpartum HPV vaccination, with 97% of women satisfied with the choice and 98% finding it convenient. However, only 30.7% completed the full three-dose vaccination series.
3) The presenter's experience vaccinating over 200 women in India postpartum found 99% compliance, with women reporting it was convenient and recommending it to friends
Post partum period an excellent opportunity for hpv vaccinationLifecare Centre
1) A study in Brazil found that HPV prevalence in young primiparous women was 58.5%, with 17.3% and 13.3% positive for the two high-risk HPV types 16 and 18. This suggests that postpartum vaccination could provide protection against cervical cancer for many women.
2) A US study found high acceptance of postpartum HPV vaccination, with 97% of women satisfied with the choice and 98% finding it convenient. However, only 30.7% completed the full three-dose vaccination series.
3) The presenter's experience vaccinating over 200 women in India postpartum found 99% compliance, with women reporting it was convenient and recommending it to friends
Safety Of the Influenza vaccine In pregnancy Lifecare Centre
Dr. Sharda jain,Life care centre
Safety of Inactivated Influenza Vaccines – WHO –SAGE position paper ,
The study found no evidence of increased RR or HR for
Major birth defects,
spontaneous abortion, or
Small for gestational age infants in pregnant women vaccinated with trivalent or monovalent influenza vaccine .
Jill Blumenthal, MD
Assistant Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
Addressing the counseling challenges in HPV vaccinationLifecare Centre
The document discusses the challenges of HPV vaccination in India. It notes that India accounts for a large proportion of the global cervical cancer burden, with over 96,000 new cases and 60,078 deaths annually. While screening is important for prevention, current screening coverage in India is only 3.1%. The document then outlines several common barriers to HPV vaccination among healthcare providers and patients. It seeks to address these barriers by providing concise responses and emphasizing that vaccination provides the highest protection when received before sexual debut or HPV exposure. It argues that OBGYNs are well-positioned to provide catch-up vaccination opportunities.
La primera publicación sobre la Vacuna recombinante, virus vivo, tetravalente para Dengue (CYD-TDV), que muestra la eficacia en dos trials: uno en Asia Pacífico (CYD14 trial) y en Latinoamérica (CYD15 trial), con mas de 31,000 participantes, entre 2 y 16 años de edad.
To evaluate the awareness about human papilloma virus (hpv) vaccine in the pr...pharmaindexing
This study evaluated awareness of the HPV vaccine for cervical cancer prevention among 500 medical students in Mumbai, India. The key findings were:
- 96% of participants were aware that HPV causes cervical cancer, but only 69.4% were aware a vaccine is available.
- Awareness of vaccine availability in India was 56.2% and only 27.6% knew the recommended target population for vaccination.
- The most common source of information was electronic media like the internet.
- Only 6% of participants had received the HPV vaccine despite its availability.
- Most (79.6%) felt inadequate information was the main barrier to vaccination programs in India.
- Overall acceptance of the HPV vaccine was 67
Similar to Cervical Vaccines in India - Recent Updates, Gardasil Jalandhar feb 2017 (20)
Impact of Social Media on Mental Health.pptxGaurav Gupta
## Social Media: The Ups and Downs for Young Minds
**Uncover the impact of social media on children's mental health.**
This presentation explores the complex relationship between social media and the developing minds of children. We'll delve into:
* **The positive connections:** How social media fosters friendships, self-expression, and access to information.
* **The potential pitfalls:** Increased anxiety, depression, body image issues, and cyberbullying.
* **Strategies for healthy use:** Explore practical tips for parents and educators to promote safe and balanced social media habits in children.
**Equip yourself with the knowledge to guide young people in navigating the social media landscape.**
Good evening everyone, and thank you for joining me today. Today we’ll be exploring the impact of social media on the mental health of children and adolescents. Social media is an undeniable part of our lives, and pediatricians are in a unique position to guide parents and children in navigating this digital landscape.
How AI will transform Pediatric Practice - Feb 2024Gaurav Gupta
Creating a concise and compelling summary for a SlideShare presentation on "How AI Will Transform Pediatric Practice" involves highlighting key points that emphasize AI's potential benefits, challenges, and future implications in pediatric healthcare. Here's a structured summary that could be effectively used in your SlideShare:
---
**Title: Transforming Pediatric Practice: The Role of AI**
**Introduction:**
- Briefly introduce the current state of pediatric practice, emphasizing the importance of accurate diagnosis, personalized treatment, and efficient healthcare delivery.
- Introduce Artificial Intelligence (AI) as a transformative tool in medicine, with a focus on pediatrics.
**AI's Impact on Diagnostics:**
- Highlight how AI algorithms enhance diagnostic accuracy in pediatric care, enabling early detection of diseases through pattern recognition in imaging, genomics, and clinical data.
- Discuss case studies where AI has successfully identified pediatric conditions earlier and more accurately than traditional methods.
**Personalized Treatment Plans:**
- Explain how AI contributes to the development of personalized medicine in pediatrics, considering the unique genetic, environmental, and lifestyle factors of each child.
- Provide examples of AI systems recommending customized treatment protocols and monitoring disease progression in real-time.
**Operational Efficiency and Patient Care:**
- Illustrate AI's role in streamlining administrative tasks, scheduling, and patient flow, allowing healthcare professionals to focus more on patient care.
- Discuss AI-powered virtual health assistants and chatbots that provide 24/7 support and guidance to caregivers, answering questions and offering advice based on medical guidelines.
**Challenges and Ethical Considerations:**
- Address the challenges of integrating AI into pediatric practice, including data privacy, ethical considerations, and the need for robust training data.
- Discuss the importance of balancing AI tools with human oversight to ensure compassionate and empathetic patient care.
**The Future of AI in Pediatrics:**
- Envision a future where AI not only supports clinical decision-making but also predicts health outcomes, identifies potential public health crises, and contributes to global pediatric health research.
- Highlight the importance of interdisciplinary collaboration in developing AI tools that are ethical, equitable, and truly beneficial for child health.
**Conclusion:**
- Summarize the transformative potential of AI in pediatric practice, emphasizing its role in enhancing healthcare delivery, improving patient outcomes, and paving the way for innovative treatment approaches.
- Call to action for healthcare professionals, researchers, and technologists to collaborate in harnessing the power of AI for the betterment of pediatric healthcare.
Latest GINA guidelines for Asthma & COVIDGaurav Gupta
What are the changes from 2019 onwards till 2022, in the GINA guidelines for developing countries like India.
Includes COVID guidelines and also a FUN QUIZ !
Talk about why these guidelines have changed - use of ICS - formoterol combination for treating even intermittent asthma
Dr Naveen Kini, Pediatrician from Bengaluru talks about WHAT is podcasting, HOW we can listen to podcasts, WHY doctors should create podcasts and much more. Co-hosted with Dr Gaurav Gupta. In arrangement with dIAP and CMIC. This is PART 1 - we discuss how to create a simple free & easy podcast in part 2 - check the presentation on slideshare under my account
Podcast creation for doctors (Pediatricians)Gaurav Gupta
To create a doctor podcast, one must first develop a clear concept focused on a specific medical area of interest. Then, choose an attention-grabbing name related to the topic and register the podcast on major platforms like Apple Podcasts and Spotify to reach a wide audience. Basic recording equipment like a computer and quality microphone are sufficient to produce clear audio. Promoting the podcast through one's website, social media, and practice's blog is key to growing the listener base.
Hep a Live & Inactivated vaccines in IndiaGaurav Gupta
dIAP presentation for GSK - Havrix and comparison of Live and inactivated Hepatitis A vaccines in Dec 2020.. Online discussion about the various Hep A vaccines available and their pros and cons
Prevention of influenza in relation to COVID 19 - the TWINDEMICGaurav Gupta
What is the concern about the TWINDEMIC of COVID 19 & Influenza?
My talk on the digital IAP platform in Dec 2020 for the pediatricians across the country
Top 10 practical questions about Flu Vaccine in India!Gaurav Gupta
What does a practising paediatrician want to to know about the Flu vaccination? Talk for Abbott Vaccines (Influvac Tetra) in Oct 2020 about common queries that doctors have about the flu vaccine in India, including how it may help in COVID-19?
Helping doctors avoid COVID in their Office PracticeGaurav Gupta
Tips for doctors and their patients to avoid Coronavirus during OPD practice in India. From a Pediatrician's perspective. How can we take supplements prophylactic medicines like Vit D, Vit C, Zinc, etc. and medicines like HCQ or Ivermectin to prevent COVID during seeing patients in our practice.
Digital eye strain - Computer vision syndrome for students during Online clas...Gaurav Gupta
Dr. Poonam Gupta, Eye Specialist from Charak Clinics, Mohali, talks with Aakash Institute about Computer vision syndrome, Digital Vision Syndrome, Eye fatigue in students doing online classes during the lockdown. How to prevent it and treat with with simple steps including the 20-20-20 rule etc.
Prevenar e cme june 2020 & FAQs & COVID Clinic QuestionsGaurav Gupta
Lockdown E-CME & Webinars - this one is on Pfizer vaccine - Prevenar,
We have also discussed the common questions on Pneumonia & how to run clinical practice during COVID shutdown
Digital waste management pedicon 2020 Indore, preconference workshopGaurav Gupta
What is important and relevant about Digital waste management pedicon 2020 Indore, preconference workshop. How to dispose of your printers, computers, mobile phones, relevant to India
How to Advertise yourself with simple office tools PEDICON 2020 Indore workshop 8 jan, 2020. How to use whatsapp, blogs, youtube facebook to advertise yourself online
Zyvac TCV - The Indian Typhoid Conjugate VaccineGaurav Gupta
The document discusses a new typhoid conjugate vaccine called Zyvac-TCV developed by Zydus Vaccines. It provides details of a phase II/III clinical trial conducted to evaluate the immunogenicity and safety of Zyvac-TCV compared to another licensed typhoid conjugate vaccine. The results showed that Zyvac-TCV was non-inferior in inducing seroconversion and had a comparable safety profile. No serious adverse events were reported for either vaccine. The document concludes that Zyvac-TCV met the immunogenicity and safety endpoints for efficacy.
Dr. Gaurav Gupta - Should you be buying an E-bike this Diwali?
Dr RP Bansal- Feeding difficulties in the newborn
Dr Nivedita- Tips on how to Continue Breast Feeding
Dr Ridhi- Teething tips
Dr Arushi - First afebrile seizure
Dr Amit - Mesentric lymphadenopathy
Dr Gunjan - Acute events following immunization plus update on BCG adenitis
Dr Sandip Jain- Tips for examining children
Dr Diljot - Mefenemic acid as an antipyretic
Dr Jaskaran- colicky infant : knowledge , attitude and practices
Dr Shailesh - School se chutti kitne din karayein ?
Dr Gaurav- Is it oral Herpes? Visual Quiz
At the four front of flu vaccination - Quadrivalent Flu Vaccination in India ...Gaurav Gupta
Is flu vaccination needed in India? Is there any benefits of Quadrivalent Flu vaccination over Trivalent Flu vaccination? Any safety & efficacy data about Vaxiflu 4 by Zydus Vaccines. All discussed in a Presentation in Panchkula, in September 2019
Meningococcal disease sep 2019 National Epidemiology & Indian recommendationsGaurav Gupta
This document discusses meningococcal disease in India, including past outbreaks, current epidemiology and surveillance data, and recommendations for vaccination. It notes that while India has a poor surveillance system and diagnostic challenges, meningococcal disease is present and the country has seen outbreaks every 6-8 years. Surveillance data from 2012-2016 shows several states regularly report over 100 cases annually. Current recommendations from the Indian Academy of Pediatrics advise vaccination for high-risk groups, international travelers, and Hajj/African meningitis belt pilgrims. While antibiotics can treat the disease, vaccination is an effective prevention strategy given unknowns around antibiotic resistance and underdiagnosis.
Japanese encephalitis - Sep 2019 India epidemiology - Is vaccination needed?Gaurav Gupta
1) Japanese encephalitis (JE) is a viral disease spread by mosquitoes that is endemic in many parts of Asia and the Pacific. India reports the highest number of JE cases annually, with an estimated actual number between 15,000-20,000 cases per year.
2) JE vaccination is the most important preventive measure according to WHO and IAP guidelines. The national vaccination program in India recommends routine vaccination with two doses of JE vaccine for children up to 15 years of age in endemic areas.
3) While mosquito and pig control efforts have not proven reliable at controlling JE, vaccination is currently the single most effective public health approach for prevention in India given the disease burden.
Research in pediatrician office - my story! NORC Aug 2019 New DelhiGaurav Gupta
Presented in NORC - Aug 2019 - National Original Research convention, discussion of Flu like illnesses and the Flu vaccination and drug utilization reviews and prescription audits and various other original research presented and published by Dr. Gaurav Gupta in his years of clinical practice, including yellow fever, Complementary medicines, drug costs and prescriptions analysis
What nelson forgot 4 - Super CME for Common Pediatric OPD questionsGaurav Gupta
What nelson forgot 4 - Super CME for Common Pediatric OPD questions, 12th July 2019
Common Office practice questions, answered in just 5-10 minutes per topic ...
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
3. WIIFY ?
• Is Cervical Cancer Vaccine Important?
• Latest schedules? When & Why?
• Does it work – real world effectiveness?
• Comparing vaccines?
• Safety
• Improving coverage
• The Future
10. Increased Risk of HPV Infection in Young Females:
Progression of the Transformation Zone
Adolescent females may have
increased susceptibility to HPV
infection, compared with adults.
During and after puberty, the
transformation zone is
particularly vulnerable to
infection and carcinogenesis.1,2
~99% of HPV-related genital
cancers arise within the
transformation zone of the
cervix.1
1. Castle PE. J Low Genit Tract Dis. 2004;8:224–230.
2. 2. ACOG Committee on Adolescent Health Care. Obstet Gynecol. 2004;104:891–898.
SCJ = squamocolumnar junction.
11. Exposure to HPV at a Young Age Increases the Risk of
Cervical Lesions and Cancer in Women[1]
1
2
3
4
5
6
7
CIN Invasive Cervical Cancer
RelativeRiskEstimatesa
≤17
18–22
aMantle-Haenszel estimates adjusted for age only.
1. La Vecchia C et al. Cancer. 1986;58:935–941.
Relative risks for CIN and invasive cancer increase with decreasing age of first
sexual intercourse.
Age at First
Intercourse (Years)
(n=206) (n=327)
Reference Population: First intercourse 23 years of age or never
5 times higher risk
of Invasive cancers
12. 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Age at Enrollment (Years)
500
700
900
1100
1300
1500
1600
SerumcLIAGMTWith
95%CI,mMU/mL
Adolescent Females Young Adult Females
Serum anti-HPV 6 responses 1
month after completion of
vaccination regimen
Per-protocol immunogenicity
population (ages 9–26)a
aInclusive of protocols 007, 013, 015, 016 and 018; all GMTs measured using competitive Luminex® immunoassay;
women 24–26 years of age were omitted in the figure because of small numbers. Similar results were observed for HPV 11, 16, and 18.
GMT = geometric mean titer.
1. Giuliano AR et al. J Infect Dis. 2007;196:1153–1162.
Higher Immune Response in
Adolescents Versus Young Adults1
13. SAGE = Strategic Advisory Committee of Experts; WHO = World Health Organization.
1. World Health Organization. Wkly Epidemiol Rec. 2009;84:1–16.
Vaccination is most effective when given to females naïve to
infection with vaccine-related HPV types
Primary target population is likely to be girls 9 or 10 through
13 years of age
WHO SAGE Recommendations:
Primary Target Population for
Vaccination1
15. Sankaranarayanan et al, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
multicentre prospective cohort study Published online December 1, 2015 www.thelancet.com/oncology
16. Salient features of the study
• Large,multicentre,prospective study.
• Indian data
• Comparison of 2D vs 3D
Sankaranarayanan et al, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
multicentre prospective cohort study Published online December 1, 2015 www.thelancet.com/oncology
17. Global Investigators List
• IARC, Lyon, France: Dr Rengaswamy
Sankaranarayanan, Dr Richard Muwonge, Mr Eric
Lucas, Dr Tarik Gheit, Dr Massimo Tommasino, Dr
Catherine Sauvaget
• DKFZ, Heidelberg, Germany: Dr Michael Pawlita,
Julia Butt, Dr Angelika Michel, Dr Tim Waterboer,
Dr Martina Willhauck-Fleckenstein, Dr Martin
Müller, Ute Koch,
• Monika Oppenländer EMBL, Heidelberg,
Germany: Dr Peter Sehr
Sankaranarayanan et al, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
multicentre prospective cohort study Published online December 1, 2015 www.thelancet.com/oncology
18. Indian Investigators List
Sankaranarayanan et al, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
multicentre prospective cohort study Published online December 1, 2015 www.thelancet.com/oncology
19. Study sites-9
Hyderabad, Osmanabad, Dindigul
Pune, Mumbai
Ahmedabad
Delhi
Gangtok ,Aizwal
Sankaranarayanan et al, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
multicentre prospective cohort study Published online December 1, 2015 www.thelancet.com/oncology
20. Aim
• To compare the immunogenicity and frequency of
persistent infection and cervical precancerous lesions
caused by vaccine-targeted HPV after vaccination with:
• two doses of quadrivalent vaccine on days 1 and 180 or later
• with three doses on days 1, 60, and 180 or later, in a cluster-
randomised trial.
• Study was designed to be done in nine locations (188
clusters) in India.
Sankaranarayanan et al, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
multicentre prospective cohort study Published online December 1, 2015 www.thelancet.com/oncology
21. Study design and Participants
• Participants were unmarried girls aged 10–18
years vaccinated in four cohorts:
• girls who received three doses of vaccine on days 1, 60, and
180 or later,
• two doses on days 1 and 180 or later,
• two doses on days 1 and 60 by default, and
• one dose by default.
• a multicentre, cluster-randomised trial in India
from Sept 1, 2009-Apr 2010 and median FU
was 4.7yr.
Sankaranarayanan et al, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
multicentre prospective cohort study Published online December 1, 2015 www.thelancet.com/oncology
22. Primary outcomes
• Immunogenicity outcomes:
– HPV-L1 genotype-specific binding Ab
concentrations (Geometric mean MFI)
– Antibody avidity (Geometric mean avidity index)
– Ab concentrations specific for neutralising
epitopes in HPV-L1 using GMTs
• Infection outcomes:
– first incident and persistent infections of vaccine
targeted HPV types during follow-up.
Sankaranarayanan et al, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
multicentre prospective cohort study Published online December 1, 2015 www.thelancet.com/oncology
23. Assessments done
• Ab titres: Blood samples obtained by nurses during
the vaccination session at a clinic or during
household visits on day 1 and months
7,12,18,24,36,48,60 from a cohort.
• Cervical samples: Pelvic examination done at 18
months after marriage or 6 months after delivery of
their first child, whichever was earlier and every year
thereafter for 3 years.
Sankaranarayanan et al, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
multicentre prospective cohort study Published online December 1, 2015 www.thelancet.com/oncology
24. Results:Subject recruitment
17729 girls
(10-18yr)
1D default (n=4950) (28%)
Day1
2D default (n=3452) (19%)
Days 1 & 60
2D (n=4979) (28%)
Days1,180
3 D (n=4348) (25%)
Days 1,60,180
Sankaranarayanan et al, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
multicentre prospective cohort study Published online December 1, 2015 www.thelancet.com/oncology
25. Results:Mean MFI
HPV types 16, 18, 6, and 11 L1 antibodies
Dashed lines show the threshold (cutoff ) values for seroconversion. MFI=median fluorescence intensity. *MFI values for month 7 were used for
the three-dose and two-dose vaccine groups, whereas MFI values for month 12 were used for the two-dose default and one-dose default groups.
26. Results: Persistent infection
• In 838 women for whom two or more samples were
available for analysis, there were no persistent HPV
16 and 18 infections in any of the four study groups
at a median follow-up of 4·7 years
Sankaranarayanan et al, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
multicentre prospective cohort study Published online December 1, 2015 www.thelancet.com/oncology
27. Adverse events• Median follow-up was 4·7 years (IQR 4·2–5·1).
• Local and systemic reactions within 15 days of
administering 34856 vaccine doses in the study included:
injection-site pain (number of reactions; n=1092),
low-grade fever (n=293),
injection-site swelling (n=124),
dizziness (n=64),
Headache (n=49),
nausea (n=30),
skin rash (n=15),
diarrhoea (n=13),
abdominal cramps (n=13), and
fainting attacks (n=10).
• No serious adverse events were attributable to the
vaccine.
Sankaranarayanan et al, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
multicentre prospective cohort study Published online December 1, 2015 www.thelancet.com/oncology
28. Summary
• Two doses of quadrivalent HPV vaccine (10-18yr),
administered with an interval of 180 days or more
between doses are:
immunologically non-inferior to the three-dose schedule
and
afford protection against incident and persistent HPV 16, 18,
6, and 11 infections
similar to that afforded by three doses
– The findings support the WHO recommendation to use
two doses separated by 6 months or more for vaccination
of young girls.
Sankaranarayanan et al, Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
multicentre prospective cohort study Published online December 1, 2015 www.thelancet.com/oncology
29. Recommendations: Gardasil 2-dose
IAP Recommendations
• Only 2 doses of either of the 2 HPV vaccines for adolescent/pre-adolescent girls
aged 9-14 years.
• For girls 15 years and older and immunocompromised individuals 3 doses are
recommended
• For 2 –dose schedule, the minimum interval between doses should be 6
months
• For 3 dose schedule, the doses can be administered at 0, 1-2 (depending on
brands) and 6 months.
VASHISHTHA et al, Indian Academy of Pediatrics (IAP) Recommended Immunization Schedule for Children Aged 0 through 18 years – India, 2014 and Updates
on Immunization VOLUME 51__OCTOBER 15, 2014
30. Current Global Experience: Countries Currently Implementing
Alternate Dosing Schedules
Canada
Quebec &
BC
Mexico Switzerland Colombia South Africa Brazil Austria
Schedule
Quebec
0-6 months
0-6-60 months 0-4 or 0-6 months 0-6 months 0-6 months 0-6-60 months 0-6 months
BC
0-6-36 months
Starting
age
Quebec
9 y.o girls
(4th grade)
9 years old 11-14 y.o. girls
(First dose before
15th birthday)
9-18 y.o. girls
(4th grade –
12th grade)
9 -10 y.o. girls 11-13 y.o. girls in
2014
9-11 y.o. girls in
2015
9 y.o boys &
girls
BC
11 to 12 y.o.
girls
(6th grade)
3rd dose
Quebec: No 3rd
D
BC: 14 to 15 y.o.
(9th grade)
Third dose if
proven necessary
Third dose
being
considered
(at month 60)
Third dose if
proven necessary
Third dose being
considered
(at month 60)
Brand
Choice
2013/2014
100% Gardasil
Since Launch
2013 MOH:
100% Cervarix
Previously GRD
90% Gardasil
Since Launch
100% Gardasil
Since Launch
100% Cervarix 100% Gardasil
Most probably
Gardasil
3
0
31. 31
Gardasil® 2-Dose: Global Regulatory Status (73)
7 NORTH AMERICA
Canada Jamaica
Mexico El Salvador
Costa Rica Honduras
Dominican Republic
ASIA PACIFIC
Hong Kong Thailand
Korea Philippines
Taiwan Sri Lanka
Malaysia Pakistan
Singapore Indonesia
Kazakhstan
SOUTH AMERICA
Brazil Venezuela
Colombia
Argentina
Peru
Ecuador
Trinidad & Tobago
MIDDLE EAST &
AFRICA
Brunei Turkey
Israel
South Africa
EUROPE
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Serbia
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Lithuania
Luxembourg
Malta
Macedonia
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Bosnia &
Herzegovina
Merck Regulatory Affairs, February 2016
33
7
11
CIS Countries
Armenia Georgia
Aruba Moldova
Azerbaijan Ukraine
Turkmenistan Uzbekistan
Belarus Russian Federation
10
4
32. QUIZ
• Arshnoor, 24 years, Female, has just
completed 3 doses of HPV vaccine. She wants
to know if she needs PAP smear testing, as she
is protected?
34. Study Groups & Duration
• Gr 1 (n=259): 9-13yr-2 doses of Gardasil (0,6m)
• Gr 2 (n=261): 9-13yr-3 doses of Gardasil (0,2,6m)
• Gr 3 (n=310):16-25yr-3doses of Gardasil (0,2,6m)
• Duration of follow up=36m
Dobson SRM et al.JAMA 2013;309 (17):1793-1802
35. Summary
• Immunogenicity of a 2-dose schedule at 0 and 6 months in girls 9
through 13 years of age is statistically noninferior for HPV-16 and
HPV-18 to the immunogenicity in women receiving 3 doses,
assessed 1 month after the final dose.
• The GMTs in girls receiving a 2-dose schedule were between 1.77-
to 2.24-fold higher than those in women receiving a 3-dose
schedule, assessed 1 month after the final dose.
Dobson SRM et al.JAMA 2013;309 (17):1793-1802
36. CONCLUSION
Based on the:
Clinical Trial data
WHO Recommendation
IAP Recommendation and
Approval in key countries
Gardasil is now approved to be used in a 2-dose alternative
schedule, at 0 and 6 months, for children 9 to 14 years old, in
India.[1]
1. Gardasil PI India
37. Quiz
• We inadvertently gave HPV vaccine to a
woman who didn't know she was pregnant at
the time. How should we complete the
schedule?
40. Why Genital Wart data is Important?
A reduction in the incidence of GWs is one of the first
markers of the effectiveness of HPV vaccination at a
population level, as they develop over a few months,
whereas precancerous lesions and cancer usually
develop over several years.
1
1. Blomberg et al: Clinical Infectious Diseases 2013;57(7):929–34
41. Five Years Into qHPV Vaccination Program, Significant Declines in
Rates of Genital Warts in Australian Females <30 Years of Age1
aAnalyses included a total of 34,900 females.
Figure reproduced from BMJ, Ali H et al, 346, f2032, 2013, with permission from BMJ Publishing Group Ltd.
1. Ali H et al. BMJ. 2013;346:f2032.
Year
20
18
16
12
10
8
6
4
2
0
14
2004 2005 2006 2007 2008 2009 2010 2011
Prevaccine period Vaccination period
Ptrend <0.001
Ptrend <0.001
Patients(%)
–72.6%
–92.6%
qHPV vaccine introduced <21 years (n=9,405)a
21–30 years (n=15,228)
>30 years (n=10,246)
• Significant decline in proportion of females diagnosed with genital warts
at first visit seen during qHPV vaccination period, especially in those
<21 years of age.
Proportion of Australian-Born Women Diagnosed as Having Genital Warts at First
Visit, by Age Group, 2004 to 2011
42. 1. Oliphant J et al. N Z Med J. 2011;124:51–58.
New Zealand: Impact of qHPV Vaccine
on Genital Warts1
63%
reduction
%First-visitclients
withgenitalwarts
2010a
43. 0
10
20
30
40
50
60
70
80
90
100
10–13 14–16 17–19 20–22 23–26 ≥27
Vaccine Effectiveness Against Genital Warts Was Greatest
in Females Vaccinated at a Younger Age
qHPV Vaccine Effectiveness: A Swedish National Cohort Study1
aEstimated effectiveness for women 27 years of age and older was <0 (95%CI: <0–13).
Estimated Effectiveness of qHPV Vaccination on Incidence
Rates of Genital Warts, by Age Group
Age (years)
Estimatedeffectiveness(%)
• Maximum reduction in incidence decreased with increasing age.
• No reduction in incidence was seen for those ≥27 years of age.
a
Amy Leval, Eva Herweijer, Alexander Ploner et al Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study J Natl Cancer
Vaccine effectiveness was highest in girls vaccinated before age 14 years
(effectiveness = 93%, 95% CI = 73% to 98%)
44. Improving Coverage
• Make it about Cervical Cancer
• Male vaccination
• Counsel about warts
• During routine f/u
• Post partum